Author

admin

Browsing

A longtime ally of former President Joe Biden is appearing before House investigators on Thursday, the eighth ex-White House aide to be summoned for Oversight Committee Chair James Comer’s probe.

Michael Donilon served as senior advisor to the president for the entirety of Biden’s four-year term.

He’s now expected to sit down with House Oversight Committee staff for a closed-door transcribed interview that could last several hours.

Comer, R-Ky., is investigating whether Biden’s top White House aides concealed signs of mental decline in the then-president, and if that meant executive actions were signed via autopen without his knowledge.

Donilon will likely be of key interest to investigators, considering his decades-long working relationship with the former president.

He first began working for Biden in 1981 as a strategist, pollster, and media advisor, according to a biography by the Harvard University Institute of Politics, where he was a Spring 2025 fellow.

Biden was serving as a senator from Delaware at the time.

He also served as chief strategist on Biden’s 2020 and 2024 campaigns before Biden dropped his re-election bid in July 2024.

The loyal former aide accused the Democratic Party of melting down earlier this year after top left-wing leaders forced Biden out of the 2024 presidential race over his disastrous debate against current President Donald Trump.

‘Lots of people have terrible debates. Usually the party doesn’t lose its mind, but that’s what happened here. It melted down,’ he said at a Harvard event in February.

It comes after another close former aide, ex-counselor to the president Steve Ricchetti, appeared before investigators for his own transcribed interview on Wednesday.

Like Ricchetti, Donilon is appearing on voluntary terms – the fifth ex-Biden aide to do so.

Three of the previous six Biden administration officials who appeared before the House Oversight Committee did so under subpoena. Ex-White House physician Kevin O’Connor, as well as former advisors Annie Tomasini and Anthony Bernal, all pleaded the Fifth Amendment during their compulsory sit-downs.

But the four voluntary transcribed interviews that have occurred so far have lasted more than five hours, as staff for both Democrats and Republicans take turns in rounds of questioning.

‘You were reportedly responsible for erecting a wall between the former president and senators ‘to shield Biden from bad information.’ Recently, during an event at Harvard University, you displayed your willingness to speak about the former president’s cognition but you reportedly ‘denounced claims that the president’s acuity and judgment declined,” Comer wrote in a June letter to Donilon asking him to appear.

‘The scope of your responsibilities—both official and otherwise—and personal interactions within the Oval Office cannot go without investigation. If White House staff carried out a strategy lasting months or even years to hide the chief executive’s condition—or to perform his duties—Congress may need to consider a legislative response.’

This post appeared first on FOX NEWS

President Donald Trump hammered back at former Russian President Dmitry Medvedev’s warnings about war with the United States, telling the deputy chairman of Russia’s Security Council to ‘watch his words.’ 

‘I don’t care what India does with Russia. They can take their dead economies down together, for all I care,’ Trump wrote on TRUTH Social at midnight Thursday. ‘We have done very little business with India, their Tariffs are too high, among the highest in the World. Likewise, Russia and the USA do almost no business together. Let’s keep it that way, and tell Medvedev, the failed former President of Russia, who thinks he’s still President, to watch his words. He’s entering very dangerous territory!’

In response to Trump’s post, Medvedev referenced Russia’s ‘Dead Hand’ – the Cold War-era automated nuclear retaliation system developed by the Soviet Union. 

‘If a few words from a former Russian president provoke such a nervous reaction from the supposedly mighty President of the United States, then clearly Russia is in the right – and will continue on its chosen path,’ Medvedev wrote on Telegram. 

‘And as for all that talk about the ‘dead economies’ of India and Russia, or about ‘venturing into dangerous territory’ – well, maybe he should rewatch some of his favorite zombie movies,’ he added. ‘And also remember just how dangerous the supposedly mythical ‘Dead Hand’ system can be.’ 

In theory, the ‘Dead Hand,’ described by the West during the 1980s as a Russian doomsday device, is meant to guarantee a massive retaliatory nuclear strike even if Moscow’s leadership is destroyed or incapacitated. 

While in Scotland on Monday, Trump warned during public remarks that Russian President Vladimir Putin had 10 or 12 days to reach a ceasefire agreement with Ukraine, shortening a previous 50-day deadline he issued earlier this month. If Russia does not, Trump promised more ‘sanctions, tariffs, and maybe secondary tariffs’ against Moscow and the purchasers of Russian goods and energy. He lamented that repeated talks with Putin have resulted in little progress toward peace. 

‘Trump’s playing the ultimatum game with Russia: 50 days or 10,’ Medvedev complained in a post to X earlier this week. ‘He should remember 2 things: 1. Russia isn’t Israel or even Iran. 2. Each new ultimatum is a threat and a step towards war. Not between Russia and Ukraine, but with his own country. Don’t go down the Sleepy Joe road!’ 

Trump on Wednesday announced a 25% tariff on imports from India – one of the biggest consumers of Russian oil, next to China – starting on Aug. 1. The president described India as a ‘friend,’ but slammed the South Asian country’s ‘strenuous and obnoxious non-monetary’ trade barriers. Trump vowed other unspecified ‘penalties’ against India for buying most of its military equipment from Russia and Russian energy ‘at a time when everyone wants Russia to STOP THE KILLING IN UKRAINE.’ 

During an unrelated press conference, Trump noted that India and Russia are founding members of BRICSoriginally formed as a counterweight to Western institutions. 

BRICS is ‘basically a group of countries that are anti-the United States and India is a member of that, if you can believe it. It’s an attack on the dollar. And we’re not going to let anybody attack the dollar,’ Trump said. ‘We have a tremendous deficit.’

In recent days, Medvedev has also shredded the framework of the trade deal Trump reached with European Commission President Ursula von der Leyen during his recent trip to Scotland. 

Trump has repeatedly communicated that trade deals with other countries would be contingent on foreign policy alignment with the United States. 

For example, after Canada announced it was backing Palestinian statehood amid Israel’s war against Hamas terrorists in Gaza, Trump wrote Thursday, ‘That will make it very hard for us to make a Trade Deal with them.’ 

Trump, meanwhile, on Thursday celebrated this reciprocal tariffs plan after telling reporters on Wednesday that they brought ‘billions’ of dollars into the U.S. economy. 

‘Tariffs are making America GREAT & RICH Again,’ Trump wrote on social media. ‘They were successfully used against the USA for decades and, coupled with really dumb, pathetic, and crooked politicians, we’re having a devastating impact on the future, and even the survival, of our country. Now the tide has completely turned, and America has successfully countered this onslaught of Tariffs used against it.’

‘ONE YEAR AGO, AMERICA WAS A DEAD COUNTRY, NOW IT IS THE ‘HOTTEST’ COUNTRY ANYWHERE IN THE WORLD. CONGRATULATIONS TO ALL!’ Trump added. 

This post appeared first on FOX NEWS

If you haven’t heard the name Sydney Sweeney before, odds are you definitely know her name now if you consume any news at all. American Eagle featured the actress in their new ad campaign that kicked off last week, and liberal women lost their ever loving minds. 

What triggered their spiral this time? Sydney has ‘good genes’ and she’s wearing ‘jeans.’

Outrageous, I know.

This good genes/jeans word play game, well it’s a whole lot of Nazi propaganda with some racism thrown in and linked to eugenics. 

If you’re not a White liberal woman, I’ll try to simplify. In liberal math, good genes + jeans = Nazi. 

I know, that wasn’t on our flashcards growing up. 

The next time you compliment a friend on her looks, resist the urge to mention good genes. Sally down the street will think you’re calling her a Nazi, when really you just want to know what face cream she’s using.

If the good genes/jeans word play were a clue on ‘Jeopardy!’ liberals would answer: ‘I’ll take Sydney Sweeney is a Nazi for $1,000, with a side of eugenics and white supremacy.’ 

Let’s ask the politically incorrect elephant in the room question — If you’re putting a large chunk of money behind an ad to sell jeans targeted at Gen Z, are you going to put someone with good genes or bad genes in front of the camera?

To quote ‘The Godfather’ — ‘It’s not personal, it’s strictly business.’ 

It also doesn’t surprise me that the perpetually outraged liberal and mostly women who have piled on over this campaign seem to ignore one more fact. According to Fox News, ‘100 percent of net proceeds from Sweeney’s ‘Sydney Jean’ – which is embroidered with a butterfly to represent domestic violence awareness – will be donated to Crisis Text Line, a nonprofit that provides free and confidential text-based mental health support and crisis intervention.’ That sure doesn’t sound like Nazis and eugenics to me.

This week, ‘Good Morning America’ (GMA) didn’t miss the chance to showcase just how unserious they are by jumping on the jean — or gene — meltdown.

Maybe GMA gambled on their viewers not having that first cup of coffee yet, so they wouldn’t notice their fuzzy Nazi math. Is it any wonder that Americans’ trust in the media is at its lowest in more than five decades, according to a Gallup poll?

Going back to the vault, circa 1980, Brooke Shields did a Calvin Klein jeans ad with the same American Eagle/Sydney Sweeney ad vibe. ‘Genes’ and ‘jeans’ were used interchangeably, as well as phrases like ‘natural selection’ and ‘survival of the fittest.’

GMA was around back then, but I don’t recall co-host Joan Lunden doing a Nazi propaganda segment calling out Brooke Shields or Calvin Klein. Then again, that was when history was still being taught in school. 

Ironically, the eugenics trigger is the greatest self-own for White liberal elites, whose holy grail is abortion on demand — anytime, any place, any reason. Legalized abortion has long been one of the most effective ways to reduce populations who are deemed less than.

The White liberal class is largely all in. 

In 2018, then-Pope Francis said, ‘I have heard that it’s fashionable, or at least usual, that when in the first months of pregnancy they do studies to see if the child is healthy or has something, the first offer is: let’s send it away, I say this with pain. In the last century, the whole world was scandalized about what the Nazis did to purify the race. Today we do the same, but now with white gloves.’

If you’re a woman who’s ever been pregnant, or if you’re the dad supporting the woman, you know doctors highly encourage having screenings for chromosomal disorders such as Down Syndrome and Trisomy 18. They don’t do this because they can cure these chromosomal disorders in utero. They push these tests so you can eliminate the ‘less than perfect problem.’ 

If only these same liberal women were as upset about the fate of unborn babies as they are about jeans. 

Oh, and in case you’re wondering, the fact that American Eagle has ‘American’ in its name makes it obvious they’re Nazis. Thankfully, self-appointed experts have the freedom to warn us all from a non-American platform like X.

This week is one of those times I’m grateful to be spending the end of the summer in the South, where sanity tends to rule the day. If I were home — where I’m outnumbered by the White liberal outrage class by about 50-1 — I’m quite confident that between their pique rage hours of Starbucks and Chardonnay, I’d be on the receiving end of the Sydney Sweeney faux fury. 

These people need a time-out — away from all cameras and keyboards … preferably with a history book.

Never underestimate the left’s ability to overplay their hand. They are screamers, but when they scream, conservatives are the ones who quietly act. Think Bud Light.

Personal finance guru Dave Ramsey likes to say the best predictor of future behavior is past behavior, so it’s no surprise that American Eagle’s stock is up more than 15% since the campaign’s rollout last week. 

I’ll be among those contributing to the rise of American Eagle’s stock when I take my girls back to school shopping. Spending my money somewhere that has the left spiraling over an imaginary offense — sign me up. 

Sydney Sweeney may have good genes, but the screamers may be the ad American Eagle never knew it needed. 

It’s back to school season, and the silent actors are shopping loudly.

This post appeared first on FOX NEWS

The canned cocktail maker High Noon is warning customers that some of its vodka seltzers were accidentally labeled as Celsius energy drinks.

In a recall notice posted to the Food and Drug Administration’s website, High Noon said an unspecified number of its Beach Variety packs contain cans are filled with High Noon vodka seltzer alcohol but have been mislabeled as Celsius Astro Vibe energy drink, Sparkling Blue Razz Edition, with a silver top.

Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition.Celsius

The products were shipped to retailers in Florida, New York, Ohio, South Carolina, Virginia and Wisconsin from July 21 to July 23.

The recall was initiated after High Noon discovered that a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon, it said.

No illnesses have been reported to date.

This post appeared first on NBC NEWS

President Donald Trump on Wednesday signed an executive order ending the de minimis trade loophole for low-value packages shipped from all countries.

The order, which takes effect Aug. 29, will subject any shipments of imported goods into the U.S. worth $800 or less to duties, the White House said.

Any goods shipped through the international postal network will be subject to tariff rates based on the value of the package and its country of origin.

The move comes after Trump in May shuttered the de minimis loophole for goods from China and Hong Kong. A federal trade court on Monday declined to block Trump’s de minimis ban, even after an auto parts retailer argued the action was unlawful and threatened its business.

Use of the de minimis provision has exploded in recent years as online shopping has become more prevalent. Ultra-cheap online retailers such as Temu and Shein have used the loophole to ship packages to American shoppers directly from China duty-free.

Shares of PDD Holdings, the parent company of Temu, dipped lower following the announcement.

The Trump administration has sought to close the loophole, calling it a “big scam” that hurts U.S. businesses. Officials have said de minimis facilitates shipments of fentanyl and other illicit substances, saying the packages are less likely to be inspected by customs agents.

The volume of de minimis shipments has skyrocketed to 309 million units so far this fiscal year, up from 115 million for all of last year, the White House said.

This post appeared first on NBC NEWS

From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. Cipher Pharmaceuticals (TSX:CPH,OTC:CPHRF)

Year-over-year gain: 48.2 percent
Market cap: C$330.79 million
Share price: C$12.33

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF in early 2024.

In addition to its current portfolio, Cipher has acquired Canadian rights to CF-101, a dermatology treatment for moderate to severe plaque psoriasis is currently expected to undergo Phase III clinical trials. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

In 2024, Cipher announced it had signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights, and the news caused Cipher’s share price to spike significantly.

During its Q1 results reporting in May 2025, the company announced a US$15 million debt repayment.

2. HLS Therapeutics (TSX:HLS)

Year-over-year gain: 42.03 percent
Market cap: C$154.95 million
Share price: C$4.90

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs. Key commercial products include Vascepa, Clozaril for treatment-resistant schizophrenia and cholesterol-lowering therapies NEXLETOL and NEXLIZET.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

3. Medexus Pharmaceuticals (TSX:MDP,OTC:MEDXF)

Year-over-year gain: 23.25 percent
Market cap: C$92.9 million
Share price: C$2.81

Medexus Pharmaceuticals specializes in bringing drugs to treat rare diseases to North America. The company manages the entire process through its fully integrated operations, from acquiring and developing drugs to marketing and selling them. Some of its key products include treatments for hemophilia B and rheumatoid arthritis, as well as a line of drugs for autoimmune diseases like lupus and allergy treatments.

In November 2024, Medexus Pharmaceuticals announced it had successfully negotiated with the pan-Canadian Pharmaceutical Alliance to make treosulfan, which Medexus commercialized in Canada under the name Trecondyv, available to publicly funded drug programs and patients. Trecondyv is indicated as part of conditioning treatment prior to bone marrow transplants in patients with certain types of blood cancers.

In addition to Canada, Medexus has the exclusive commercialization rights to treosulfan in the US, where it received approval from the US Food and Drug Administration (FDA) in January 2025.

4. Satellos Bioscience (TSXV:MSCL,OTC:MSCLF)

Year-over-year gain: 18 percent
Market cap: C$102.26 million
Share price: C$0.59

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247 targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

The company began enrolment for a multiple-ascending-dose arm of the Phase 1 study for SAT-3247 last November after no drug-related adverse events were reported in the single-ascending-dose group.

In May of this year, Satellos announced results from its Phase 1b trial, reporting SAT-3247 has shown positive safety and pharmacokinetic data and encouraging early functional results, clearing the path for a planned Phase 2 trial.

5. NurExone Biologic (TSXV:NRX,OTC:NRXBF)

Year-over-year gain: 1.41 percent
Market cap: C$44.18 million
Share price: C$0.72

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

The company released preclinical results from animal testing evaluating the efficacy of its nano-drug ExoPTEN in restoring lost vision at the end of 2024. In July 2025, preclinical studies indicated that ExoPTEN could improve walking quality in patients with spinal cord injuries.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Investor Insight

With high-quality, drill-ready assets with world-class discovery potential, Piche Resources is a compelling business case for investors looking to leverage a bull market for uranium and gold.

Overview

Piche Resources (ASX:PR2) is an ASX-listed mineral exploration company focused on uranium and gold exploration in Tier-1 jurisdictions: Western Australia and Argentina. The company holds 100 percent ownership of all of its projects and is supported by a highly experienced board and technical team.

Targeting globally significant discoveries in Tier-1 mineral provinces

Piche’s portfolio includes the advanced-stage Ashburton uranium project in Western Australia and two large-scale exploration projects in Argentina: the Cerro Chacon gold-silver project and the Sierra Cuadrada uranium project. These projects have delivered high-grade exploration results and are drill-ready, positioning the company to unlock significant shareholder value through systematic exploration programmes.

Piche has an internationally recognized board focused on creating long-term shareholder value, and an in-country technical team in Argentina with a proven track record of taking projects from discovery through to development.

Company Highlights

  • Flagship Ashburton uranium project in Western Australia with recent high-grade drilling results over wide intercepts.
  • Sierra Cuadrada uranium project in Argentina showing extensive near-surface mineralisation with assays up to 2.86 percent U₃O₈.
  • Cerro Chacon gold-silver project with high-grade surface results (up to 11.65 g/t gold and 333.7 g/t silver) across a 14 km mineralised corridor.
  • Fully permitted and EIA-approved for drilling at Cerro Chacon (Chacon South and Middle).
  • Large, 100-percent-owned tenement package across all projects (Ashburton: 335 sq km; Cerro Chacon: 414 sq km; Sierra Cuadrada: 1,310 km²).
  • Board of directors includes former leaders of Peninsula Energy, Orano, Rio Tinto Uranium and Barrick Gold.
  • Upcoming drill campaigns planned at Cerro Chacon and Ashburton to test multiple high-priority targets.

Key Projects

Gold: Cerro Chacon, Argentina

Cerro Chacon interpreted geology and tenement holding

Cerro Chacon is a large-scale, early-stage gold-silver exploration project located in the Chubut Province of Argentina. The project is situated within a region known for hosting world-class low-sulphidation epithermal systems, including Cerro Negro and Cerro Vanguardia. With multiple gold-bearing structures confirmed over a 14 km corridor, Cerro Chacon is emerging as a highly promising and underexplored precious metals system with substantial scale and grade potential.

Project Highlights

Location: ~40 km southwest of Paso de Indios, Chubut Province

Tenure: 414 sq km across multiple tenements

Highlights:

  • A 14 km-long mineralised corridor has been delineated across Chacon Grid, La Javiela and Toro Hosco prospects.
  • High-grade geochemical results include:
    • 11.65 g/t gold and 120.3 g/t silver at Toro Hosco
    • 333.7 g/t silver, 9.48 percent lead, and 8.57 percent zinc at La Javiela South
  • Maiden RC drilling programme of 57 holes (7,905 m) scheduled across three main targets:
    • Chacon Grid: 45 holes (5,590 m)
    • La Javiela: 8 holes (1,740 m)
    • Toro Hosco: 4 holes (575 m)
  • EIA approvals for Chacon South and Chacon Middle were received in May 2025, enabling drilling to proceed.
  • Vein systems range from 2 to 6 km in strike length and up to 50 m in width; hosted within structurally controlled low-sulphidation epithermal veins (LSEV).

Uranium: Ashburton Project, Australia

The Ashburton project is Piche’s flagship uranium exploration asset in Australia, situated in the Pilbara region of Western Australia. Located within a historically underexplored but highly prospective unconformity-related uranium district, the project provides the company with strong leverage to the growing global demand for uranium. The project is geologically analogous to world-class Proterozoic uranium systems, with multiple confirmed mineralised zones and a regional corridor of 60 km.

Project Highlights

  • Location: Pilbara region, ~1,150 km north of Perth
  • Tenure: 335 sq km following the recent application for tenement E52/4461 (214 sq km), adding to the existing 122 sq km holdings.
  • Highlights:
    • 2024 RC and diamond drilling confirmed high-grade uranium mineralisation at multiple stratigraphic levels.
    • Best intercepts include:
      • 3.45 m @ 5,129 ppm eU₃O₈ from 137.62 m (ARC006)
      • 10.48 m @ 1,412 ppm eU₃O₈ from 114.30 m (ADD005)
      • 2.42 m @ 2,681 ppm eU₃O₈ from 155.10 m (ADD003).
      • 7.86 m @ 2,266 ppm eU₃O₈ from 105.42 m (ADD006)
    • The company has outlined a 60 km structural corridor hosting multiple uranium occurrences including Angelo A & B, Canyon Creek, Ristretto and Atlantis.
    • Atlantis prospect: historical drilling returned up to 7,400 ppm U₃O₈ over 2.2 m; rock chip samples have returned up to 37 percent U₃O₈.

Uranium: Sierra Cuadrada, Argentina

Sierra Cuadrada is Piche’s primary uranium asset in Argentina, covering a vast area within the San Jorge Basin. This large-scale project has demonstrated strong surface uranium mineralisation with multiple drill-ready prospects. With mineralisation confirmed across extensive zones and supported by historical radiometric and geochemical data, Sierra Cuadrada has the potential to host multiple Tier-1 uranium deposits in a cost-effective, near-surface setting.

Teo 5 and 6 prospect 2024 auger drill programme

Project Highlights:

Location: San Jorge Basin, ~200 km north of Comodoro Rivadavia

Tenure: 1,310 sq km across multiple licences

Highlights:

  • The project area contains broad, flat-lying mineralisation at multiple stratigraphic levels.
  • High-grade uranium assays include:
    • 28,650 ppm U₃O₈ (2.86 percent) from rock chip sampling at Teo 8
    • 24,017 ppm U₃O₈ from channel sampling
    • 2,772 ppm U₃O₈ over 0.5m from auger drill sample
  • Mineralised zones extend over a strike of 60 sq km, with confirmed targets on the majority of tenements.
  • 2024 auger drilling and sampling confirmed uranium continuity across a sandstone and conglomerate sedimentary package with 14 samples exceeding 200 ppm U₃O₈.
  • Rock chip sampling has returned 114 samples >200ppm U₃O₈
  • RC drilling is planned to follow up on anomalies identified in the auger and channel sampling programmes.

Management Team

John (Gus) Simpson – Executive Chairman

John Simpson has over 37 years of experience in mineral exploration, development and mining. Previously the executive chairman and founder of Peninsula Energy Limited (ASX:PEN), a USA uranium producer.

Stephen Mann – Managing Director

Stephen Mann is a geologist with over 40 years of experience in exploration, discovery and development of mining projects, including 20 years in the uranium sector. Formerly the Australian managing director of Orano, the world’s third-largest uranium producer.

Pablo Marcet –Executive Director

Pablo Marcet is a senior geoscientist with 38 years of experience in exploration, discovery and development of mineral deposits. Currently an independent director of lithium producer Arcadium Lithium (NYSE:ALTM) and previously a director of Barrick Gold (NYSE:GOLD) and U3O8 (TSX:UWE).

Clark Beyer – Non-executive Director

Clark Beyer is an internationally recognized nuclear industry executive with over 35 years of experience. Formerly the managing director of Rio Tinto Uranium and currently principal of Global Fuel Solutions, providing strategic consulting to the international uranium and nuclear fuels market.

Stanley Macdonald – Non-executive Director

Stanley Macdonald is a nationally recognized mining entrepreneur, founding director and instrumental in the success of numerous ASX-listed companies, such as Giralia Resources, Northern Star and Redhill Iron. He is currently a director of Zenith Minerals.

This post appeared first on investingnews.com

When Canadian-Russian programmer Vitalik Buterin penned a white paper in 2013 outlining a new kind of blockchain platform, few could have predicted the seismic impact it would have on the world of finance, technology, and beyond.

Today (July 30), Ethereum turns 10 years old, marking a milestone that represents a decade of one of the most influential blockchain platforms and a testament to the growing pains, triumphs, and resilience of the decentralized movement.

How did Ethereum go from a white paper drafted by a 19-year-old to a billion-dollar ecosystem that reshaped global finance?

Read on to find out more.

What is Ethereum and who invented it?

Co-founder Buterin said in a 2016 interview that Ethereum was born out of admiration for Bitcoin’s decentralized structure and frustration at its limited capabilities.

“I thought [those in the Bitcoin community] weren’t approaching the problem in the right way. I thought they were going after individual applications; they were trying to kind of explicitly support each [use case] in a sort of Swiss Army knife protocol,” Buterin said, summarizing his motivation to build something more adaptable.

From this foundational idea, Ethereum emerged as a decentralized, programmable blockchain — a “world computer” that would host smart contracts and decentralized applications (dApps), cutting out middlemen and enabling new forms of coordination.

The foundation of the fledgling project was laid between 2013 and 2014. After releasing his white paper in late 2013, Buterin attracted a handful of co-founders, including Gavin Wood, Charles Hoskinson, Joseph Lubin, Anthony Di Iorio, Jeffrey Wilcke, Mihai Alisie, and Amir Chetrit. Together, they spearheaded a crowdfunding campaign in mid-2014 that raised over US$18 million, one of the earliest and most successful Initial Coin Offerings (ICOs) in crypto history.

Despite this momentum, the Ethereum blockchain didn’t launch until July 30, 2015. That release, dubbed “Frontier,” was a basic, raw, and developer-focused version of Ethereum designed for building the infrastructure that would follow.

ETH, Ethereum’s native coin, initially traded for under a dollar. The early months saw little market movement as ETH hovered between US$0.70 and US$2.00, supported mainly by enthusiasts and developers interested in dApp potential.

When was Ethereum’s first major peak?

Ethereum’s first major price rally came during the 2017 crypto bull run, when rising global interest in blockchain technology and the initial coin offering (ICO) boom brought ETH into the mainstream.

After beginning the year at just barely US$8, Ethereum surged to a then-record high of around US$1,400 by January 2018, capping off one of the most explosive price increases in the history of digital assets. This more than 17,000 percent rise was driven by a combination of speculative demand and the emergence of Ethereum as the preferred platform for launching new tokens via ICOs.

By early 2018, however, the market began to reverse. A sweeping crypto correction saw Ethereum’s price fall back below US$100 by the end of that year. The drawdown exposed Ethereum’s technical bottlenecks, such as high gas fees and slow confirmation times during network congestion.

What was the DAO Hack, and how did it influence Ethereum’s trajectory?

Ethereum’s ethos of decentralization was also tested early on. In 2016, an experiment in decentralized governance — the Decentralized Autonomous Organization or DAO — raised about US$150 million in ETH from the community. The idea was to create a venture capital fund governed entirely by smart contracts and token-holder votes.

But just weeks after launch, a vulnerability in the DAO’s code that allowed for recursive call exploit was discovered, draining 3.6 million ETH or about a third of the fund.

At just ten months old, Ethereum was now facing a crisis that tested its fundamental principles, chief among them the immutability of the blockchain and the inviolability of smart contracts.

Three primary responses were debated. One option was to do nothing, honoring the hacker’s actions as legitimate under the rules of the code and accepting the theft. Another was to implement a “soft fork” that would blacklist the child DAO’s address, effectively freezing the stolen funds.

The most radical option was a “hard fork” that would roll back the ledger and return all stolen Ether to the original investors, which would undo the hack entirely.

Ultimately, the hard fork went ahead, and Ethereum split into two chains: the main Ethereum chain (ETH), where the funds were returned to investors, and a new chain called Ethereum Classic (ETC), which preserved the original ledger including the DAO hack.

How has Ethereum performed post-2020?

Ethereum price performance July 30, 2015 – June 30, 2025.

Chart via TradingView.

Ethereum reached its all-time high price of US$4,878 on November 10, 2021, during the peak of the 2020–2021 crypto bull run. The rally was driven by a convergence of factors: institutional adoption of crypto, a massive expansion of decentralized finance (DeFi), and explosive interest in NFTs, most of which were built on Ethereum’s ERC-721 standard.

By late 2021, Ethereum was settling billions in daily transaction volume and powering thousands of decentralized applications, cementing its position as the leading smart contract platform.

However, the peak was short-lived. Inflation fears and global risk aversion in early 2022 triggered a sharp correction across risk assets, including crypto. Ethereum’s price dipped below US$1,000 in June 2022 amid cascading liquidations and platform collapses like Terra and Celsius.

Still, even through the drawdown, Ethereum remained the backbone of DeFi, NFT markets, and layer-2 innovation, setting the stage for its long-planned transition to proof-of-stake later that year.

In the years that followed the fork, Ethereum faced growing pressure to scale and reduce its environmental impact, particularly as DeFi and NFT activity surged.

These challenges set the stage for a major protocol overhaul: Ethereum’s transition from Proof-of-Work (PoW) to Proof-of-Stake (PoS) was considered to be one of the most ambitious technical feats in blockchain history. Officially known as “the Merge,” the upgrade combined Ethereum’s execution layer (the mainnet) with the Beacon Chain, which introduced staking-based consensus.

The Merge took place in September 2022 and the environmental impact was immediate: Ethereum’s energy consumption dropped by over 99 percent.

While the Merge had little short-term effect on price, it marked a crucial moment for Ethereum’s long-term viability. At the time of the upgrade, ETH was trading at around US$1,600, which was a sharp decline from its all-time high of US$4,891 in November 2021 during the height of the crypto bull market.

That price peak had been driven by unprecedented network demand as NFTs and decentralized finance exploded in popularity, both largely built on Ethereum. By mid-2022, however, macroeconomic tightening, rising interest rates, and a series of high-profile crypto failures, including the collapse of TerraUSD and the insolvency of major lending platforms, had triggered a broad downturn.

After the Merge, ETH remained volatile. It already lost ground by as much as 70 percent against crypto leader Bitcoin since the Merge, and the introduction of EIP-1559 in 2021 had already created a more deflationary pressure on ETH supply through base fee burns.

Despite this setback, ETH showed relative resilience compared to many altcoins. In 2023, Ethereum hovered mostly between US$1,200 and US$2,100, with price movements closely tracking investor sentiment toward regulatory developments, Bitcoin’s performance, and broader market liquidity. Institutional interest in Ethereum also grew during this period, with more funds launching ETH products and staking services expanding.

Entering 2024, Ethereum gained momentum amid improving macroeconomic conditions and renewed optimism about real-world applications for blockchain technology. The network saw moderate success in sectors like tokenized assets, layer-2 infrastructure, and decentralized identity.

ETH briefly reclaimed the US$4,000 level in early March 2024 before retreating again due to renewed regulatory scrutiny in the US. Despite the pullback, Ethereum remained the second-largest cryptoasset by market capitalization and retained the majority share of developer activity across all chains.

The 2025 Swing

Ethereum 1-year price performance, July 28, 2024 – July 28, 2025.

Chart via TradingView.

Ethereum, as well as the rest of the crypto landscape, saw a full positive swing in 2025 as regulatory clarity dominated the first half of the year.

In June, the US Senate approved the Guiding and Establishing National Innovation for US Stablecoins (GENIUS) Act with bipartisan support. President Donald Trump, now serving his second term, publicly backed the bill, calling it “a win for American innovation and financial leadership.”

The GENIUS Act establishes a regulatory framework for US-pegged stablecoins, requiring full reserve backing, independent audits, and federal licensing for large issuers. It also clarifies that qualifying stablecoins are not securities, pulling them out of the SEC’s jurisdiction and instead aligning oversight with banking regulators like the OCC and Federal Reserve.

Crucially, the law defines “payment stablecoins” as a new category of digital cash, and Ethereum has emerged as one of the largest beneficiaries of this policy shift. The majority of dollar-backed stablecoins, which include USDC, USDT, and newer entrants like PayPal USD, are issued and transacted on Ethereum.

The GENIUS Act’s legal recognition of stablecoins has given institutional players more confidence to engage with Ethereum-based infrastructure.

As a result, capital inflows into Ethereum have accelerated, with analysts noting a sharp uptick in demand for ETH as a “platform asset” powering tokenized dollars and digital settlement rails.

ETH’s price also soon followed. Following the Senate’s approval of the GENIUS Act in June 2025, ETH jumped over 25 percent in two weeks, briefly reaching US$3,824 — outperforming Bitcoin and breaking out of a multi-month consolidation range.

The act has also prompted strategic shifts among financial institutions. BlackRock, Fidelity, and JPMorgan have expanded their Ethereum-based offerings, including on-chain fund administration, tokenized treasuries, and collateralized lending protocols that rely on smart contracts.

Several US banks are also piloting internal payment rails using tokenized dollars on Ethereum rollups.

What’s next for Ethereum?

Buterin himself has acknowledged that Ethereum’s current roadmap is not the end. Speaking in late 2022 before the Merge, he noted that “Ethereum is 55 percent complete.”

The long-term vision includes greater privacy features, zero-knowledge proofs for secure scalability, and expanding the reach of dApps to a billion users.

As of mid-2025, Ethereum currently trades around US$3,400, buoyed by strong institutional adoption, continued growth of layer-2 networks like Arbitrum and Base, and early signs of real-world asset tokenization gaining traction among banks and fintech firms.

While Ethereum’s price remains well below its 2021 peak, its performance since 2020 reflects growing maturity, with fewer speculative surges and more interest anchored in a more crypto-friendly environment.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

“Whatever is out of favor and hated at the moment, that’s probably what you need to buy,” he said. “Buy it when it’s boring and no one cares, then you get to ride the wave up.”

Barton also broke down his current portfolio, which holds a 30 percent weighting in precious metals—particularly gold—citing concerns over currency policies and the long-term upside for gold and silver.

Watch the interview above for more from Barton on the similarities between poker and resource investing.

Securities Disclosure: I, Georgia Williams, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The Senate confirmed President Donald Trump’s nominee Emil Bove as a federal judge Tuesday, handing a controversial leader at the Department of Justice a lifetime role on a powerful appellate court.

Bove was narrowly confirmed to the U.S. Court of Appeals for the 3rd Circuit in a 50-49vote with no support from Democrats. His confirmation followed a contentious weeks-long vetting process that included three whistleblower complaints and impassioned outside figures voicing both support and opposition to his nomination.

Senate Judiciary Committee Chairman Chuck Grassley, R-Iowa, said from the Senate floor before the vote that he supported Bove and believed the nominee had been the target of ‘unfair accusations and abuse.’

‘He has a strong legal background and has served his country honorably. I believe he will be a diligent, capable, and fair jurist,’ Grassley said. 

Bove’s ascension to the appellate court marks a peak in his legal career.

He started out as a high-achieving student, college athlete and Georgetown University law school graduate. He went on to clerk for two federal judges and worked for about a decade as a federal prosecutor in the Southern District of New York, leading high-profile terrorism and drug trafficking cases through 2019.

Alongside Todd Blanche, now a deputy attorney general, Bove led Trump’s personal defense team during the president’s criminal prosecutions. Blanche told Fox News Digital in an interview last month that Bove was a ‘brilliant lawyer’ who authored the vast majority of their legal briefs for Trump’s cases. In a letter to the Senate, attorney Gene Schaerr called Bove’s brief writing ‘superb.’

Bove will leave behind his job as principal associate deputy attorney general at the DOJ. Attorney General Pam Bondi congratulated him in a statement.

‘This is a GREAT day for our country,’ Bondi wrote on X. ‘I cannot thank Emil enough for his tireless work and support at @TheJusticeDept. He will be missed — and he will be an outstanding judge.’

Two Republicans, Sens. Lisa Murkowski of Alaska and Susan Collins of Maine, voted against Bove.

Democrats and some who crossed paths with Bove during his time in New York and at DOJ headquarters fiercely opposed his nomination and said he was unqualified.

One whistleblower, Erez Reuveni, had become a successful prosecutor at the DOJ over the last 15 years when he was fired under Bove’s watch. Reuveni said he was party to a meeting in March in which Bove floated defying any court orders that would hinder one of Trump’s most legally questionable deportation plans, a claim Bove denies. Reuveni also said the culture at the DOJ, particularly during the most intense moments of immigration lawsuits, involved misleading federal judges and was like nothing he had experienced during his tenure, which included Trump’s first term.

Two other anonymous whistleblowers emerged at the eleventh hour during the confirmation process and vouched for Reuveni’s claims.

A spokeswoman for Grassley told Fox News Digital the third whistleblower only brought claims to Senate Democrats and did not attempt to engage with Grassley. Grassley’s staff eventually met with the whistleblower’s lawyers after the chairman’s office reached out, the spokeswoman said.

Grassley said his staff interviewed more than a dozen people to vet the initial whistleblower claims and could not find evidence that Bove urged staff to defy the courts.

‘Even if you accept most of the claims as true, there’s no scandal,’ Grassley said. ‘Government lawyers aggressively litigating and interpreting court orders isn’t misconduct—it’s what lawyers do.’

While in New York, Bove also alienated some colleagues. In 2018, a band of defense lawyers said in emails reported by The Associated Press that Bove could not ‘be bothered to treat lesser mortals with respect or empathy.’ Another lawyer who had interactions with Bove in New York told Fox News Digital he was a ‘bully’ who browbeat people. 

A group that opposes Bove’s nomination, Justice Connection, published a letter signed by more than 900 former DOJ employees calling for the Senate to reject Bove’s nomination.

Among their concerns was that Bove led the controversial dismissal of Democratic New York City Mayor Eric Adams’ federal corruption charges. Several DOJ officials resigned in protest over Bove’s orders to toss out the charges. In the letter, the former employees said Bove has been ‘trampling over institutional norms’ and that he lacked impartiality.

Senate Judiciary Committee Democrats, in an unusual move, staged a walkout at a hearing on Bove before a recent vote to advance his nomination. Senate Minority Leader Chuck Schumer, D-N.Y., called him a ‘henchman,’ a description Democrats have widely adopted for him.

‘He’s the extreme of the extreme,’ Schumer told reporters. ‘He’s not a jurist. He’s a Trumpian henchman. That seems to be the qualification for appointees these days.’

Bove defended himself against critics during his confirmation hearing.

‘I am not anybody’s henchman. I’m not an enforcer,’ Bove said. ‘I’m a lawyer from a small town who never expected to be in an arena like this.’

Fox News’ Alex Miller contributed to this report.

This post appeared first on FOX NEWS